Although Dmt1 has been previously shown to be a Hif2α target gene under low iron conditions,[21] using other stimuli such as PHD inhibition or hypoxia, the duration, concentration, and extent of the treatment could lead to variable results with Dmt1 in vivo, unlike what is seen during iron deficiency. The gene discussed is SLC11A2; the disease is Iron deficiency anemia.